Floatz logo

Cediranib

Stage IV Colon Cancer

National Cancer Institute (NCI)Small moleculePhase 2Active
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Stage IV Colon Cancer cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Sun Yat-sen University
Phase 3BBB
Calcium folinate pentahydrate
Sun Yat-sen University
Phase 3BBB
Irinotecan
Sun Yat-sen University
Phase 3BBB
(+)-VINCRISTINE
Gruppo Oncologico del Nord-Ovest
Phase 3BBB
Cetuximab
Merck Sharp & Dohme LLC
Phase 3BB

View all 41 →

Same molecule, other indications

Cediranib is also rated in:

gliosarcomaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent NeuroblastomaDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Colon CancerDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →